Vergara-Pérez Hugo, Diaitz-Usetxi Laplaza Raúl, Pérez Alba Alejandro, Baliño Remiro Pablo, Rius Peris Asunción, Fenollosa Segarra M Ángeles, Tamayo Vasquez Alejandro, Reque Javier
Nephrology Department, Hospital General Universitario de Castellón, Castellón de la Plana, Spain.
Radiology Department, Hospital General Universitario de Castellón, Castellón de la Plana, Spain.
Blood Purif. 2025;54(1):37-43. doi: 10.1159/000541233. Epub 2024 Sep 12.
For hemodialysis (HD) patients, the selection of vascular access is a crucial factor that significantly affects morbidity and mortality. Historically, native arteriovenous fistulas (AVFs) have been established using surgical techniques. However, devices facilitating percutaneous endovascular arteriovenous fistula (endoAVF) formation have recently been introduced in clinical practice, showing promising initial evidence. The primary objectives were technical success, efficacy, and cannulation rates. The secondary objectives included primary and cumulative patency, safety, and the number of procedures required to maintain fistula patency.
A prospective, single-center, single-arm study included all patients who underwent endoAVF creation using the WavelinQ™ EndoAVF System at a University Hospital between December 2021 and August 2023.
A total of 20 patients who underwent an endoAVF were included. Technical success was 100%. In total, 75% (15) of the endoAVFs met the criteria for physiological suitability. The cannulation rate was 66% (10/15) for endoAVFs that reached physiological suitability. At 6 months of follow-up, the primary and cumulative patency rates were 65% and 75%, respectively; at 12 months, these were 50% and 70%, respectively. Serious adverse events were not observed. The reintervention rate was 0.33 procedures/patient-year.
Based on our experience, creating AVFs using the WavelinQ 4-F EndoAVF System is safe and effective, with high technical success rates and acceptable patency and reintervention rates.
对于血液透析（HD）患者而言，血管通路的选择是一个至关重要的因素，会显著影响发病率和死亡率。从历史上看，自体动静脉内瘘（AVF）一直通过外科技术建立。然而，近年来，有助于经皮血管腔内动静脉内瘘（endoAVF）形成的装置已引入临床实践，并初步显示出良好效果。主要目标是技术成功率、有效性和插管率。次要目标包括初始通畅率和累积通畅率、安全性以及维持内瘘通畅所需的手术次数。
一项前瞻性、单中心、单臂研究纳入了2021年12月至2023年8月期间在某大学医院使用WavelinQ™ EndoAVF系统进行endoAVF创建的所有患者。
总共纳入了20例行endoAVF手术的患者。技术成功率为100%。总体而言，75%（15个）的endoAVF符合生理适用性标准。达到生理适用性的endoAVF的插管率为66%（10/15）。在随访6个月时，初始通畅率和累积通畅率分别为65%和75%；在12个月时，分别为50%和70%。未观察到严重不良事件。再次干预率为0.33次手术/患者年。
根据我们的经验，使用WavelinQ 4-F EndoAVF系统创建AVF是安全有效的，技术成功率高，通畅率和再次干预率可接受。
